Questions & explanations
1. Compare the quality control requirements for a kit-prepared radiopharmaceutical versus a cyclotron-produced one.
Kit-prepared radiopharmaceuticals (like technetium-99m from a generator) are made by adding eluate to a cold kit. QC focuses on radiochemical purity, pH, and particle size (if it's a colloid). Cyclotron-produced radiopharmaceuticals (like gallium-67 or indium-111) come as a ready-to-use solution, but QC must verify the radionuclidic purity (no other radioactive contaminants) and the specific activity (radioactivity per mass). For cyclotron products, tests for long-lived impurities are important because they can increase patient dose. Both types require sterility and endotoxin testing, but the methods differ. Overall, kit products need more frequent on-site QC, while cyclotron products rely on manufacturer QC certificates.
2. How can clinicians minimize thyroid stunning in patients undergoing radioiodine therapy for thyroid cancer?
Clinicians can minimize stunning by using I-123 instead of I-131 for diagnostic scans, as I-123 causes less radiation damage. They can also use the lowest possible diagnostic activity (dose) of I-131, typically less than 2 mCi. Another strategy is to avoid a diagnostic scan altogether and rely on other imaging like ultrasound or thyroglobulin levels. If a diagnostic scan is necessary, they can schedule the therapy within a few days of the scan to avoid prolonged stunning, or wait several weeks for recovery. Additionally, using a single high-dose therapy without a preceding diagnostic scan is an option for some patients. These approaches help ensure that the therapeutic dose is effectively taken up by thyroid cells.
3. How is a rising thyroglobulin level managed in a patient with negative imaging?
A rising thyroglobulin (Tg) level with negative imaging (e.g., negative neck ultrasound and diagnostic whole-body scan) suggests microscopic disease that is not visible. Management options include: close observation with serial Tg measurements every 6-12 months; empiric radioiodine therapy (giving a therapeutic dose of I-131 without a positive scan); or using alternative imaging like FDG PET/CT, which can detect dedifferentiated cancer. For example, if Tg rises from 2 to 10 ng/mL over a year, empiric therapy with 150 mCi of I-131 may be given, followed by a post-therapy scan to locate disease. If FDG PET/CT shows uptake, the disease may be radioiodine-refractory, and other treatments are considered.
4. How does a diagnostic dose of I-131 cause stunning before therapy?
When a diagnostic dose of I-131 (a radioactive form of iodine) is given for a scan, it emits radiation that can damage the sodium-iodide symporter (NIS) on thyroid cells. The NIS is the protein that actively transports iodine into the cells. This damage reduces the cells' ability to take up iodine for several days to weeks. If a larger therapeutic dose of I-131 is given during this period, the cells may not take up enough iodine to kill them effectively. The stunning effect is more likely with higher diagnostic doses and longer intervals between the scan and therapy. To minimize stunning, doctors may use a lower diagnostic dose or a different isotope like I-123, which emits less damaging radiation.
5. Give an example of how patient-specific factors affect absorbed dose in thyroid therapy.
A patient with a large thyroid gland (e.g., 80 grams) will receive a lower absorbed dose per unit administered activity compared to a patient with a small gland (e.g., 20 grams) if the same activity is given, because the dose is spread over more tissue. For example, if 555 MBq (15 mCi) of I-131 is given, the absorbed dose to an 80-gram thyroid might be 50 Gy, while a 20-gram thyroid receives 200 Gy. Also, patients with high iodine uptake (e.g., 80% at 24 hours) will have a higher cumulated activity and thus a higher absorbed dose than those with low uptake (e.g., 20%). Therefore, dosimetry allows adjustment of the administered activity to achieve a target dose, such as 300 Gy for Graves' disease.
6. What is absorbed dose in radiation dosimetry?
Absorbed dose is the amount of radiation energy deposited per unit mass of tissue. It is measured in grays (Gy), where 1 Gy equals 1 joule per kilogram. In thyroid nuclear medicine, absorbed dose is calculated for both diagnostic and therapeutic procedures to ensure that the target tissue (e.g., thyroid or cancer) receives enough radiation to be effective while minimizing damage to surrounding healthy tissues. For example, in radioiodine therapy for hyperthyroidism, the absorbed dose to the thyroid is typically around 200-300 Gy. Dosimetry helps personalize treatment by adjusting the administered activity (amount of radioactive material) based on factors like thyroid size and iodine uptake.
7. Compare the use of diagnostic whole-body scan (DxWBS) and stimulated thyroglobulin in detecting recurrence.
A diagnostic whole-body scan (DxWBS) uses a small dose of I-131 or I-123 to image iodine-avid tissue. Stimulated thyroglobulin (Tg) is measured after TSH stimulation (by withdrawal or recombinant TSH). Both are used to detect recurrence, but stimulated Tg is more sensitive for small-volume disease. For example, a patient with a negative DxWBS but a stimulated Tg of 10 ng/mL likely has disease that is not visible on scan. Conversely, a positive DxWBS with undetectable Tg may indicate non-functioning tissue. Current guidelines often recommend stimulated Tg as the primary test, with DxWBS reserved for high-risk patients or when Tg is positive. Combining both provides complementary information.
8. Give an example of a follow-up schedule for a low-risk thyroid cancer patient using thyroglobulin and imaging.
A low-risk patient (e.g., small tumor, no lymph node involvement) after total thyroidectomy and radioiodine ablation might have the following follow-up: at 6-12 months, measure suppressed Tg and TgAb, and perform neck ultrasound. If Tg is <0.2 ng/mL and ultrasound is normal, the patient is considered disease-free. Then, annual follow-up with suppressed Tg and ultrasound is done. Stimulated Tg is not routinely needed. If Tg becomes detectable (e.g., 0.5 ng/mL), a stimulated Tg and possibly a diagnostic whole-body scan are performed. For example, a patient with Tg 0.8 ng/mL on suppression may undergo a stimulated Tg test; if it rises to 5 ng/mL, further imaging like FDG PET/CT is considered.
9. Why is bone marrow dose a concern in radioiodine therapy dosimetry?
Bone marrow is sensitive to radiation and can be damaged by circulating radioactive iodine in the blood. The absorbed dose to bone marrow must be kept below a safe limit, typically less than 2 Gy, to avoid myelosuppression (reduced blood cell production). This is especially important in thyroid cancer patients who receive high activities of I-131 (e.g., 3.7-7.4 GBq or 100-200 mCi). Dosimetry calculates the marrow dose based on the blood activity and the patient's weight. For example, if a patient's blood activity suggests a marrow dose of 2.5 Gy, the administered activity may be reduced. In some cases, dosimetry-guided therapy can increase the effectiveness while keeping marrow dose safe.
10. How is radioiodine-refractory disease diagnosed?
Radioiodine-refractory disease is diagnosed when a patient with differentiated thyroid cancer has at least one of these findings: (1) a metastatic lesion that shows no I-131 uptake on a diagnostic whole-body scan, (2) a lesion that takes up I-131 but continues to grow despite therapy, (3) progression after a large cumulative dose of I-131 (e.g., >600 mCi), or (4) some lesions take up I-131 while others do not (mixed response). For example, a patient with lung metastases that are visible on CT but show no uptake on a post-therapy scan is considered refractory. The diagnosis is confirmed by imaging (e.g., FDG PET/CT showing uptake in non-iodine-avid lesions) and rising thyroglobulin levels.
11. How is the absorbed dose to the thyroid calculated in radioiodine therapy?
The absorbed dose is calculated using the formula: D = A × S, where D is the absorbed dose, A is the cumulated activity (total number of radioactive decays in the tissue), and S is the S-factor (dose per unit cumulated activity). The cumulated activity is estimated from the administered activity (e.g., in MBq or mCi) and the biological half-life of iodine in the thyroid. The S-factor depends on the radionuclide (e.g., I-131) and the mass of the thyroid. For example, a typical administered activity of 555 MBq (15 mCi) of I-131 for Graves' disease may deliver an absorbed dose of about 200 Gy to a 20-gram thyroid. Accurate dosimetry requires measuring thyroid uptake at multiple time points.
12. What is radioiodine-refractory thyroid cancer?
Radioiodine-refractory (RAI-refractory) thyroid cancer is a type of differentiated thyroid cancer (like papillary or follicular) that no longer takes up enough radioactive iodine (I-131) to be effectively treated with it. This means that the cancer cells have lost their ability to concentrate iodine, often due to changes in the sodium-iodide symporter (NIS) or other cellular pathways. It is defined by at least one of the following: a metastatic lesion that does not take up I-131 on a scan, a lesion that progresses despite I-131 uptake, or progression after a cumulative I-131 activity of >600 mCi. These patients need alternative therapies because radioiodine is no longer effective.